Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.

摘要: Background: Concurrent chemoradiotherapy (CRT) is a standard of care in the treatment unresectable locally advanced non-small cell lung cancer (NSCLC). At Rush University Medical Center, patients with NSCLC are treated split-course CRT an attempt to maximize efficacy and tolerability. We reviewed our experience since 1999. Subset analysis was performed on poor-risk patients. Methods: All diagnosis stage IIIA/IIIB definitive between January 1999 December 2008 were included this retrospective study. The primary end point overall survival. Poor-risk defined accordance ongoing cooperative group trials. Results: One hundred forty-four identified, 35% IIIA 65% IIIB. There 52 92 average-risk Median survival for all 20.4 months actuarial 32.1% 3-year rate. demonstrated median 22.1 months, statistically indistinguishable from remainder cohort ( p = 0.21). Acute esophagitis mild, 3% rate grade 3 no cases 4 or 5. Conclusions: Split-course appeared effective delivered favorable toxicity profile. experienced better than expected Prospective evaluation must be completed before it can considered option NSCLC.